Evelo Biosciences
Evelo Biosciences raises $75M Series D at $500M valuation
Evelo Biosciences: Series D Funding Round
Evelo Biosciences has successfully raised $75M in Series D funding, reaching a valuation of $500M.
Company Overview
Monoclonal microbials for cancer and inflammation
Funding Details
The Series D round was led by Fidelity, with participation from Celgene, Kaiser Permanente Ventures, Flagship Pioneering.
Company Information
- Headquarters: 620 Memorial Drive, Cambridge, MA 02139
- Founded: 2014
- Employees: 150+
- Category: Biotech
Investment
Evelo Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series D
- Celgene: Verified investor in Series D
- Kaiser Permanente Ventures: Verified investor in Series D
- Flagship Pioneering: Verified investor in Series D
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free